Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aciphex · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rabeprazole Sodium Delayed-Release Tablets 20 mg |
| 2 | ACTIVE_COMPARATOR | Aciphex® Delayed-Release Tablets 20 mg |
| Name | Type | Description |
|---|---|---|
| Rabeprazole Sodium Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fasting |
| Aciphex® Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...
Aciphex is a small molecule drug being developed by Viatris Inc. (VTRS). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and the therapeutic area is classified as Other.
Aciphex is being studied for use in healthy individuals. It is currently in Phase 1 clinical development, with one completed trial involving 72 participants. The drug is not yet approved and remains investigational.
Aciphex is developed by Viatris Inc., a company traded under the ticker symbol VTRS. The drug is currently in Phase 1 clinical development.
Aciphex is in Phase 1 clinical development. It has one completed trial with 72 enrolled participants. The drug is investigational and not yet approved for any indication.
Aciphex has one completed clinical trial, NCT00648349, titled 'Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex Delayed-Release Tablets 20 mg'. This Phase 1 trial enrolled 72 healthy volunteers in the United States.
Aciphex is being studied in comparison to rabeprazole sodium delayed-release tablets in a clinical trial. The trial NCT00648349 compares Aciphex delayed-release tablets 20 mg to rabeprazole sodium delayed-release tablets 20 mg.